GLIOBLASTOMA

This early-phase study tests a personalized DNA vaccine for people with a fast-growing brain cancer called glioblastoma. The vaccine is custom-made for each patient based on their tumor's unique genetic changes. The goal is to see if the vaccine is safe and can train the immune s…

This study tests whether adding the drug indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers (glioblastoma, medulloblastoma, ependymoma, or DIPG) live longer without their cancer growing. Indoximod works by blocking a natural…

This study tests whether removing a larger margin of brain tissue around a glioblastoma tumor (beyond what is standard) can help people live longer. It involves 90 adults with suspected glioblastoma who are healthy enough for surgery. The approach aims to remove more hidden cance…

This early-phase trial tests whether adding the drug AZD1390 to standard radiation can help people with a fast-growing brain tumor called glioblastoma. About 97 participants with either new or returning tumors will receive the drug before and during radiation. The study first che…

This early-stage study tests an oral drug called gallium maltolate in 26 people whose glioblastoma (a severe brain cancer) has returned after standard treatment. The main goal is to find a safe dose and see if it can slow tumor growth. Participants take the drug by mouth and are …

This study tests a combination of two drugs, L19TNF and lomustine, in 90 adults whose glioblastoma (a fast-growing brain cancer) has come back or worsened. The goal is to find the safest and most effective dose by monitoring side effects and survival at 12 months. Participants mu…

This study tests whether the drug tofacitinib can slow tumor growth in people with recurrent glioblastoma, a fast-growing brain cancer. About 17 adults whose cancer has returned after standard treatment will take tofacitinib pills twice daily. The main goal is to see how long the…

This program provides an experimental drug called gallium maltolate (GaM) to adults with glioblastoma, a severe brain cancer, that has returned or not responded to standard treatments. It is for patients aged 18 and older who have run out of other options and may still benefit. T…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This early-phase study tests whether specially engineered immune cells (CAR T cells) can safely target and destroy brain tumor cells that have spread to the lining of the brain and spinal cord. Ten adults with glioblastoma, ependymoma, or medulloblastoma will receive these cells.…

This early-phase study tests a radioactive drug called [177Lu]Lu-DOTA-TATE in people with glioblastoma, an aggressive brain cancer. For newly diagnosed patients, the drug is added to standard radiation and chemotherapy. For those whose cancer has returned, it is given alone. The …

This early-phase study tests the safety and best dose of an experimental drug called ruxolitinib when added to standard brain cancer treatment (radiation and temozolomide) for people with newly diagnosed aggressive brain tumors. About 60 adults with grade III gliomas or glioblast…

This early-phase study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people whose glioblastoma has come back after initial treatment. The goal is to see if the drugs are safe and can boost the immune system to fight the tumor. About 46 particip…

This study tests whether two targeted drugs, dabrafenib and trametinib, given after radiation therapy can help children and young adults (up to age 25) with a specific type of aggressive brain cancer called BRAF V600-mutant high-grade glioma. The drugs block proteins that help th…

This study tests whether adding the drug veliparib to standard radiation and chemotherapy can help children and young adults with a fast-growing brain tumor called high-grade glioma. The drug works by blocking a protein that helps tumor cells repair themselves, making them more s…

This early-phase study tests a new treatment for glioblastoma, a fast-growing brain tumor. The therapy uses a patient's own immune cells, modified to target a protein called CD70 on tumor cells and to better reach the brain. The main goals are to see if the treatment is safe and …

This early-phase study tests a modified herpes virus designed to attack brain tumor cells directly. The virus is injected into the tumor, and some participants also receive a drug to boost the immune response. The main goal is to find the safest dose and see how the body reacts. …

This early-phase study tests two immunotherapy drugs (nivolumab and ipilimumab) given before surgery in people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if the drugs are safe and how they affect immune cells in the tumor. About 63 participants wi…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 52 adults will receive the combination therapy to see if it improves survival and cont…

This early-stage trial tests whether adding the drug ibrutinib to standard radiation and chemotherapy (temozolomide) is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. The study involves 36 participants and looks for the highest safe dose of ibrutin…

This early-phase study tests whether specially engineered immune cells can safely treat recurrent or treatment-resistant malignant glioma, a type of brain cancer. About 29 participants will receive memory-enriched T cells that are modified to recognize and attack HER2-positive tu…

This phase 3 trial tests whether giving a dose of radiation directly to the tumor cavity during surgery can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 314 adults aged 18 to 80 with operable brain tumors will receive either standa…

This study tests whether adding the immunotherapy drug nivolumab to radiation and another drug called bevacizumab can help people with a returning type of brain cancer called glioblastoma. The trial includes 39 adults whose tumors have a specific genetic marker (MGMT methylated) …

This early-phase study tests whether adding the experimental drug azeliragon to standard radiation and chemotherapy (temozolomide) is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 18 participants will receive the combination to find the best…

This study tests a combination of a drug (niraparib) and a device that delivers low-intensity electric fields (Tumor-Treating Fields) in 30 adults whose glioblastoma has come back after radiation. The goal is to see if the treatment can shrink or stabilize the tumor and to check …

This phase 2 trial tests whether the immunotherapy drug nivolumab can stop or slow the growth of IDH-mutant gliomas, a type of brain tumor. The study includes 62 adults whose tumors have a high number of mutations (hypermutator phenotype) or not. Participants receive nivolumab in…

This early-phase study tests whether adding high-dose vitamin C and an iron-based drug (ferumoxytol) to standard radiation and chemotherapy can help control glioblastoma, an aggressive brain tumor. About 17 adults with newly diagnosed glioblastoma will receive these added treatme…

This early-stage trial tests a new approach for people with newly diagnosed glioblastoma, a fast-growing brain cancer. The treatment combines two DNA vaccines (INO-5401 and INO-9012) with an immunotherapy drug (cemiplimab), plus standard radiation and chemotherapy. The goal is to…

This early trial tests a new imaging method called qOBM that uses light to help surgeons see the edges of brain tumors during surgery. About 24 adults with certain brain tumors will take part. The goal is to see if the tool is safe and reliable for finding tumor margins.

This early study looks at how two experimental drugs, defactinib and VS-6766, enter glioblastoma tumors in the brain. Fourteen adults with new or returning glioblastoma will take a single dose before surgery. The main goal is to measure drug levels in the tumor and surrounding br…

This study explores whether adding weekly MRI scans during radiation treatment for high-grade glioma (a fast-growing brain tumor) can help doctors adjust the radiation plan to better target the tumor. About 20 adults with newly diagnosed glioma will receive standard radiation plu…

This study looks back at the outcomes of chemotherapy and targeted therapy in 1000 adults with recurrent malignant gliomas, including glioblastoma and anaplastic astrocytoma. Researchers will analyze survival and progression times to understand which treatments work best. The goa…